Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04949750
Other study ID # IRB-VNO1002
Secondary ID R01AG064688
Status Recruiting
Phase N/A
First received
Last updated
Start date September 6, 2022
Est. completion date October 31, 2024

Study information

Verified date September 2023
Source University of Medicine and Pharmacy at Ho Chi Minh City
Contact Trang M. Tong, Dr
Phone +84 919280403
Email trang.tm@umc.edu.vn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of paper-based cognitive training in Vietnamese patients with early Alzheimer's disease


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - For patient: - Diagnosis of Probable Alzheimer's Disease per DSM-5 criteria; - In the early stage of AD (MMSE from 20 to 25); - Age from 60 - 80 years old; - Had greater than 5 years of formal education. - For Caregiver: - Members (including, but not limited to partners, children, relatives, lived-in helper of the patient) that are important for care delivery and provide care-related tasks (eg personal care, eating, cooking, cleaning) and everyday decision making to the patients. They are not required to live together or spend a specific amount of time with the patients; - Older than 18 years of age; - Possess adequate Vietnamese language skills and no cognitive impairment to conduct interview and evaluation Exclusion Criteria: - For patient: - Patients with concomitant diseases (heart failure, kidney failure, liver failure or thyroid diseases) that affect cognitive functions; - Diagnosed with significant neurologic disease other than AD (Parkinson's disease, multi-infarct dementia, schizophrenia, history of significant head trauma followed by persistent neurologic defaults, …), major depression within the past 1 year, or taking psychoactive medications (antidepressants with significant anticholinergic side effects, neuroleptics, chronic anxiolytics or sedative hypnotics, etc) within the past 1 month; - Having major visual, auditory, reading, or writing impairments; - Patients and/or caregivers who decline to participate. - For cargiver: - Having subjective complaints of cognitive impairment prevents them from understanding the instruction from the research team; - Having significant visual, auditory, reading, or writing impairments; - Caregivers who decline to participate

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Paper - based cognitive training
Cognitive training

Locations

Country Name City State
Vietnam University Medical Center Ho Chi Minh City

Sponsors (4)

Lead Sponsor Collaborator
University of Medicine and Pharmacy at Ho Chi Minh City National Geriatric Hospital, National Institute on Aging (NIA), University of California, Davis

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in the Mini-Mental State Examination (MMSE) It is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. The score is between 0-30. Higher score indicating better cognition. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the Memory tests Immediate Recall, Delayed Recall, Delayed Recognition are tests that measure memory function. Higher score indicating better cognition. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the Trail Making test scores Raw score, assessing attention, executive function. TMT is divided into two parts, TMT-A and TMT-B. In the TMT part A, circles with number from 1 to 25 are arranged randomly. Numerical sequence should be connected by patients as quickly as possible, cutoff value > 180 seconds. In the TMT part B, patients must alternate between numbers and letters, cut off value > 300 second. Cutoff scores indicate the value above suggest cognitive performance is normal. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the Digits Span forward and backward The longest digits of forward and backward are 8 and 7, respectively. The total scores are twelve for each test. Higher score indicating better cognition. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the Verbal fluency test Semantic memory score will be measured using the Verbal fluency test. The verbal fluency test is a short test of verbal functioning. Participants are given 1 min to produce as many animals as possible within a semantic category (category fluency). The participant's score is the number of animals. Higher score means better cognition. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the Clock drawing test 1-6 points, with higher scores indicating worse visuo-spatial function. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the 15-Item Version of the Boston Naming Test Cognitive test of semantic memory. Object naming to confrontation, which also depends upon intact perceptual and word retrieval ability. Higher scores indicating better cognition. 12 weeks from baseline cognitive assessment
Primary Change from baseline in the Instrumental Activities of Daily Living (IADL) score. Instrumental Activities of Daily Living (IADL) is a questionnaire to assess patient's capacity to live independently. 12 weeks from baseline cognitive assessment
Secondary Change from baseline in the Zarit Burden Interview (ZBI) score. Zarit Burden Interview score is a questionnaire to assess patient's caregiver burden. 12 weeks from baseline cognitive assessment
Secondary Percentage of participants completes the full 12-week cognitive training. Every 4 weeks participants will follow-up at Dementia Center and be able to continue the training if they complete 80% of each level of difficulty workload. Therefore, we aim to calculate the percentage of participants who can completes the full 12-week cognitive training. 12 weeks from baseline cognitive assessment
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A
Withdrawn NCT02707978 - F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) Phase 2